Jiao Cai

No. 270, Rongdu Avenue, Jinniu District, Sichuan, P.R. China
Chengdu, 610083, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

SETD2 inhibited T-cell acute lymphocytic leukemia invasion and infiltration by inhibiting the JAK/STAT pathway.

SETD2 inhibited T-cell acute lymphocytic leukemia invasion and infiltration by inhibiting the JAK/STAT pathway.

Journal: Molecular and cellular biochemistry

Published: August 06, 2025

Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial.

Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial.

Journal: Journal of hematology & oncology

Published: June 03, 2025

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial.

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial.

Journal: Journal of hematology & oncology

Published: April 01, 2025

Rapid development of acute monocytic leukemia (AML-M5b) with t(9;11)(p22;q23) after chemotherapy for T-cell lymphoblastic lymphoma: A case report.

Rapid development of acute monocytic leukemia (AML-M5b) with t(9;11)(p22;q23) after chemotherapy for T-cell lymphoblastic lymphoma: A case report.

Journal: Heliyon

Published: March 03, 2024

Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT.

Case report: Successful treatment of Chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT.

Journal: Medicine

Published: October 06, 2023

Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy.

Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy.

Journal: Frontiers in medicine

Published: July 24, 2023

Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis.

Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis.

Journal: Journal of bone oncology

Published: July 13, 2023

Effect of miR-381-3p/FGF7 axis on the osteogenic differentiation of bone marrow mesenchymal stem cells through MEK/ERK signaling pathway.

Effect of miR-381-3p/FGF7 axis on the osteogenic differentiation of bone marrow mesenchymal stem cells through MEK/ERK signaling pathway.

Journal: Tissue & cell

Published: November 21, 2021

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Journal: Frontiers in medicine

Published: July 30, 2021

Green synthesis of fluorescence carbon nanoparticles from yum and application in sensitive and selective detection of ATP.

Green synthesis of fluorescence carbon nanoparticles from yum and application in sensitive and selective detection of ATP.

Journal: Luminescence : the journal of biological and chemical luminescence

Published: May 22, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026